Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.53 CHF | -0.13% | -3.68% | +0.78% |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Sales 2024 * | 48.15B 42.73B | Sales 2025 * | 50.2B 44.55B | Capitalization | 211B 187B |
---|---|---|---|---|---|
Net income 2024 * | 10.05B 8.92B | Net income 2025 * | 11.04B 9.8B | EV / Sales 2024 * | 4.63 x |
Net Debt 2024 * | 11.49B 10.2B | Net Debt 2025 * | 10.14B 8.99B | EV / Sales 2025 * | 4.41 x |
P/E ratio 2024 * |
18.8
x | P/E ratio 2025 * |
16.6
x | Employees | 76,057 |
Yield 2024 * |
3.87% | Yield 2025 * |
4% | Free-Float | 86.29% |
Latest transcript on Novartis AG
1 day | -0.13% | ||
1 week | -2.93% | ||
Current month | -4.43% | ||
1 month | -3.29% | ||
3 months | +0.87% | ||
6 months | -7.29% | ||
Current year | +0.78% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 18 M€ | +4.89% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 85.53 | -0.13% | 2,541,879 |
24-03-15 | 85.64 | -1.34% | 16,109,810 |
24-03-14 | 86.8 | -0.38% | 2,717,302 |
24-03-13 | 87.13 | -0.53% | 3,547,186 |
24-03-12 | 87.59 | -1.36% | 3,766,221 |
Delayed Quote Swiss Exchange, March 18, 2024 at 12:31 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.78% | 212B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+11.39% | 308B | |
-6.09% | 210B | |
-2.92% | 203B | |
-3.72% | 158B | |
-5.94% | 144B |